Two Sigma Advisers
AMRX icon

Two Sigma Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Two Sigma Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-117,049
Closed -$1.47M – 116
2025
Q4 		$1.47M Buy
117,049
+84,800
+263% +$970K ﹤0.01% 1305
2025
Q3 		$323K Sell
32,249
-14,200
-31% -$127K ﹤0.01% 1949
2025
Q2 		$376K Sell
46,449
-142,600
-75% -$1.08M ﹤0.01% 1873
2025
Q1 		$1.58M Buy
189,049
+145,200
+331% +$1.21M ﹤0.01% 1253
2024
Q4 		$347K Sell
43,849
-32,400
-42% -$272K ﹤0.01% 1918
2024
Q3 		$634K Sell
76,249
-163,000
-68% -$1.27M ﹤0.01% 1606
2024
Q2 		$1.52M Sell
239,249
-103,400
-30% -$656K ﹤0.01% 1343
2024
Q1 		$2.08M Sell
342,649
-96,400
-22% -$544K ﹤0.01% 1203
2023
Q4 		$2.67M Sell
439,049
-13,700
-3% -$61K 0.01% 1126
2023
Q3 		$1.91M Buy
452,749
+79,300
+21% +$296K ﹤0.01% 1236
2023
Q2 		$1.16M Buy
373,449
+53,900
+17% +$115K ﹤0.01% 1481
2023
Q1 		$444K Buy
319,549
+69,300
+28% +$138K ﹤0.01% 1986
2022
Q4 		$498K Buy
250,249
+192,549
+334% +$432K ﹤0.01% 1878
2022
Q3 		$117K Sell
57,700
-120,549
-68% -$338K ﹤0.01% 2287
2022
Q2 		$567K Sell
178,249
-53,500
-23% -$194K ﹤0.01% 1852
2022
Q1 		$966K Sell
231,749
-82,200
-26% -$364K ﹤0.01% 1651
2021
Q4 		$1.5M Buy
313,949
+155,100
+98% +$773K ﹤0.01% 1329
2021
Q3 		$848K Buy
158,849
+104,700
+193% +$527K ﹤0.01% 1695
2021
Q2 		$277K Sell
54,149
-214,600
-80% -$1.22M ﹤0.01% 2164
2021
Q1 		$1.81M Buy
+268,749
New +$1.49M 0.01% 1315
2020
Q4 		– Sell
-47,249
Closed -$183K – 2374
2020
Q3 		$183K Sell
47,249
-190,100
-80% -$813K ﹤0.01% 2176
2020
Q2 		$1.13M Sell
237,349
-72,800
-23% -$300K ﹤0.01% 1516
2020
Q1 		$1.08M Buy
310,149
+17,400
+6% +$73.7K ﹤0.01% 1443
2019
Q4 		$1.41M Buy
292,749
+22,200
+8% +$77.2K ﹤0.01% 1400
2019
Q3 		$785K Buy
+270,549
New +$944K ﹤0.01% 1538
2018
Q3 		– Sell
-257,765
Closed -$4.23M – 2220
2018
Q2 		$4.23M Buy
+257,765
New +$4.52M 0.01% 923

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Two Sigma Advisers's AMRX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 117,049 shares — an estimated $1.47M sold.

Two Sigma Advisers first reported a position in AMRX in Q2 2018 and held it in 26 quarters. The position peaked at $4.23M in Q2 2018. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 117,049 Amneal Pharmaceuticals shares in Q1 2026, an estimated $1.47M.
  • Two Sigma Advisers first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 26 quarters.
  • Two Sigma Advisers's Amneal Pharmaceuticals position peaked at $4.23M in Q2 2018.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.